NCT03854149View on ClinicalTrials.gov

Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

CompletedOBSERVATIONAL
Enrollment

218

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

April 30, 2023

Study Completion Date

May 30, 2023

Conditions
Congenital Heart DiseaseAtrial ArrhythmiaThromboembolismAnticoagulants Causing Adverse Effects in Therapeutic Use
Trial Locations (4)

12462

Attikon University Hospital, Athens

15123

Mitera Children's Hospital, Athens

17674

Onassis Cardiac Surgery Centre, Athens

54636

AHEPA University Hospital, Thessaloniki

All Listed Sponsors
collaborator

Onassis Cardiac Surgery Centre

OTHER

collaborator

Attikon Hospital

OTHER

collaborator

MITERA Children's Hospital

UNKNOWN

lead

AHEPA University Hospital

OTHER

NCT03854149 - Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study | Biotech Hunter | Biotech Hunter